Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 5/20 | 0.36 |
| ▸ | MAOA | P21397 | 4/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 3/20 | 0.35 |
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948622 | 0.85 | BACE1 (0.38) | HRH3MAOBMAOAABHD6BRD4 | |
| SCHEMBL9948033 | 0.85 | MAOB (0.45) | HRH3MAOBMAOABACE1APP | |
| SCHEMBL9948154 | 0.83 | BACE1 (0.52) | BACE1APP | |
| SCHEMBL16125941 | 0.82 | BACE1 (0.46) | BACE1APP | |
| SCHEMBL18867063 | 0.81 | BACE1 (0.39) | MAOBMAOAABHD6BACE1APP | |
| SCHEMBL9947869 | 0.80 | BRD4 (0.40) | MAOBMAOABRD4BACE1APP | |
| SCHEMBL9959213 | 0.79 | ABHD6 (0.38) | MAOBMAOAABHD6BACE1APP | |
| SCHEMBL12747715 | 0.79 | MAOB (0.55) | HRH3MAOBMAOA | |
| SCHEMBL16622126 | 0.79 | BACE1 (0.39) | MAOBMAOABACE1APP | |
| SCHEMBL11805867 | 0.79 | METAP1 (0.47) | MAOBDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3176172-B1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2020-01-29 | — | — | EP | disclosed |
| EP-3176172-B1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2020-01-29 | — | — | EP | disclosed |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2019-03-19 | — | — | US | disclosed |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2019-03-19 | — | — | US | disclosed |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2018-08-09 | — | — | US | disclosed |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2018-08-09 | — | — | US | disclosed |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2018-08-09 | — | — | US | disclosed |
| US-9918985-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2018-03-20 | — | — | US | disclosed |
| US-9918985-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2018-03-20 | — | — | US | disclosed |
| US-9918985-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2018-03-20 | — | — | US | disclosed |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | ASTRAZENECA INTELLECTUAL PROPERTY | 2013-08-15 | — | — | US | disclosed |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | ASTRAZENECA INTELLECTUAL PROPERTY | 2013-08-15 | — | — | US | disclosed |
| WO-2013054108-A1 | MONO-FLUORO BETA-SECRETASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-04-18 | — | — | WO | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012087237-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | BACE1, BACE2, APP | HRH3 2646/4885MAOB 75/4885MAOA 136/4885 |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | BACE1, BACE2, APP | HRH3 2646/4885MAOB 75/4885MAOA 136/4885 |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | BACE1, BACE2, APP | HRH3 2646/4885MAOB 75/4885MAOA 136/4885 |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | HRH3 2646/4885MAOB 75/4885MAOA 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.